Gallic acid induces apoptosis and inhibits cell migration by upregulating miR-518b in SW1353 human chondrosarcoma cells

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 91-98

  Liang, Wenna ^a   Li, Xihai ^a   Li, Yachan ^a   Li, Candong ^a   Gao, Bizheng ^a   Gan, Huijuan ^a   Li, Sumin ^a   Shen, Jianying ^a   Kang, Jie ^a   Ding, Shanshan ^a   Lin, Xuejuan ^a   Liao, Linghong ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Chondrosarcoma; Gallic acid; MicroRNA; Mitochondria

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; CASPASE 9; GALLIC ACID; MICRORNA; MICRORNA 518B; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL SIZE; CELL VIABILITY; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MIGRATION INHIBITION; MITOCHONDRION; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE NEOPLASMS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHONDROSARCOMA; GALLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84891909610     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2155     Document Type: Article

References (38)

1. Schrage YM, Briaire-De Bruijn IH, De Miranda NF, et al: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 69: 6216-6222, 2009.
2. Li X, Ye H, Cai L, et al: Millimeter wave radiation induces apoptosis via affecting the ratio of Bax/Bcl-2 in SW1353 human chondrosarcoma cells. Oncol Rep 27: 664-672, 2012.
3. Dickey ID, Rose PS, Fuchs B, et al: Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 86: 2412-2418, 2004.
4. Kalinski T, Sel S, Kouznetsova I, Röpke M and Roessner A: Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract 205: 339-345, 2009.
5. Yuan J, Dutton CM and Scully SP: RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 23: 1467-1474, 2005.
6. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al: The clinical approach towards chondrosarcoma. Oncologist 13: 320-329, 2008.
7. Bovée JV, Cleton-Jansen AM, Taminiau AH and Hogendoorn PC: Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 6: 599-607, 2005.
8. Zuntini M, Salvatore M, Pedrini E, et al: MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. Clin Genet 78: 507-516, 2010.
9. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
10. Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33: 1113-1120, 2012.
11. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
12. Anglicheau D, Muthukumar T and Suthanthiran M: MicroRNAs: small RNAs with big effects. Transplantation 90: 105-112, 2010.
13. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
14. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
15. Locatelli C, Filippin-Monteiro FB and Creczynski-Pasa TB: Alkyl esters of gallic acid as anticancer agents: a review. Eur J Med Chem 60: 233-239, 2013.
16. Verma S, Singh A and Mishra A: Gallic acid: molecular rival of cancer. Environ Toxicol Pharmacol 35: 473-485, 2013.
17. Kim YJ: Antimelanogenic and antioxidant properties of gallic acid. Biol Pharm Bull 30: 1052-1055, 2007.
18. Panich U, Onkoksoong T, Limsaengurai S, Akarasereenont P and Wongkajornsilp A: UVA-induced melanogenesis and modulation of glutathione redox system in different melanoma cell lines: the protective effect of gallic acid. J Photochem Photobiol B 108: 16-22, 2012.
19. Shahrzad S, Aoyagi K, Winter A, Koyama A and Bitsch I: Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 131: 1207-1210, 2001.
20. Zhang M, Zhou S, Zhang L, et al: miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma. FEBS Lett 586: 3508-3521, 2012.
21. Liang W, Li X, Li C, et al: Quercetin-mediated apoptosis via activation of the mitochondrial-dependent pathway in MG-63 osteosarcoma cells. Mol Med Rep 4: 1017-1023, 2011.
22. Kim HJ, Lee SG, Kim YJ, et al: Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. Int J Oncol 42: 1985-1992, 2013.
23. Kim SY and Helman LJ: Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 152: 517-528, 2009.
24. Russinoff S, Miran S, Gowda AL and Lucas PA: Osteosarcoma cells differentiate into phenotypes from all three dermal layers. Clin Orthop Relat Res 469: 2895-2904, 2011.
25. Liang CZ, Zhang X, Li H, et al: Gallic acid induces the apoptosis of human osteosarcoma cells in vitro and in vivo via the regulation of mitogen-activated protein kinase pathways. Cancer Biother Radiopharm 27: 701-710, 2012.
26. Liao CL, Lai KC, Huang AC, et al: Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol 50: 1734-1740, 2012.
27. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
28. Circu ML and Aw TY: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762, 2010.
29. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
30. Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004.
31. Low IC, Kang J and Pervaiz S: Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 15: 2975-2987, 2011.
32. Del Gaizo Moore V and Letai A: BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332: 202-205, 2013.
33. Fernández-Luna JL: Apoptosis regulators as targets for cancer therapy. Clin Transl Oncol 9: 555-562, 2007.
34. Lalier L, Cartron PF, Juin P, et al: Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12: 887-896, 2007.
35. Thorns C, Kuba J, Bernard V, et al: Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma. Virchows Arch 460: 371-377, 2012.
36. Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA and Vasconcelos MH: MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 47: 163-174, 2011.
37. Creighton CJ, Fountain MD, Yu Z, et al: Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 70: 1906-1915, 2010.
38. Cai CK, Zhao GY, Tian LY, et al: miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28: 1764-1770, 2012.